** Shares of drug developer Generation Bio GBIO.O rise 30% to $5.28 premarket
** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising
** Co also restructuring with about a 90% workforce reduction by end of October
** Co posted Q2 sales of $765,000, well below analysts' est of $3.1 mln - LSEG
** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG
** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins
** As of last close, stock down 61% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。